Company / R&D Expense
Eledon Pharmaceuticals, Inc. R&D Expense History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$14.6M
FY2016
5-year range
$7.4M / $14.6M
FY2014-FY2016
Trend
+19.5%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $7M to $15M over the past 2 years.
Based on SEC 10-K filings.
$15M in FY2016.
Improved from $7M to $15M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, r&d expense increased 19.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $14.6M | +19.5% |
| FY2015 | $12.2M | +65.5% |
| FY2014 | $7.4M | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026